Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome—a systematic review

Jeroen Jaspers Focks,1 Marc A Brouwer,1 Martijn G H van Oijen,2,3 Angel Lanas,4 Deepak L Bhatt,5 Freek W A Verheugt1

ABSTRACT

Background Clopidogrel as an adjunct to aspirin has improved outcomes after acute coronary syndromes, but laboratory studies suggest a reduced antiplatelet effect when proton pump inhibitors (PPIs) are co-administered. Despite corroborating data from retrospective studies, new clinical data fuel the controversy on this issue.

Purpose Systematic review of the impact of the addition of PPIs to clopidogrel on platelet function and cardiovascular outcome.


Study selection Published articles on controlled studies addressing the addition of PPIs to clopidogrel. Platelet function studies describe patients as well as healthy volunteers. Clinical studies concern patients using clopidogrel for acute coronary syndromes or because of stent implantation for stable coronary disease.

Data extraction Two investigators independently reviewed the identified articles for eligibility, and one author extracted the data.

Data synthesis In 70% (7/10) of the laboratory studies examining healthy volunteers on clopidogrel, addition of PPIs resulted in a significant reduction in platelet inhibition. For patients, this was observed in 11/18 (61%) studies. The 33 clinical studies showed significant heterogeneity in observed outcomes, with risk ratios for major adverse cardiovascular events varying from 0.64 to 4.58 in the case of PPI use, which was randomly allocated in only two studies. Consequently, imbalances between prognosticators at baseline and PPI prescription bias markedly contributed to the variability in results.

Conclusions Despite indications of reduced antiplatelet activity ex vivo in the case of PPI administration in clopidogrel users, data on the clinical consequences are controversial. With the accumulating evidence from better designed, prospective clinical studies, an adverse effect of PPI use on clinical outcome in patients on clopidogrel cannot be substantiated. This review challenges the validity of conclusions based on quantitative analyses of predominantly non-randomised data.

INTRODUCTION

Optimal antithrombotic therapy has proved to be essential in secondary prevention after an acute coronary syndrome (ACS).1 Aspirin is associated with a relative reduction of 25% in recurrent events.1 Addition of clopidogrel has resulted in a further 20% reduction, and the combination is therefore widely implemented.2 In patients who use antiplatelet agents, gastrointestinal complications are well-known side effects, which are reduced by proton pump inhibitors (PPIs).3 Therefore the current guideline is to prescribe a PPI in high-risk patients.4 However, the Food and Drug Administration (FDA) and European Medicines Agency (EMA) have published warnings about co-therapy of clopidogrel with PPIs, which initially were primarily based on laboratory and retrospective cohort studies.5–7 The former reported reduced ex vivo inhibition of platelet aggregation, indicative of a pharmacological interaction between (certain) PPIs and clopidogrel.8–10 Retrospective studies that reported adverse clinical outcomes in the case of co-therapy seemed to corroborate the laboratory findings.11,12

From a pharmacological point of view, interference with clopidogrel metabolism seems plausible and could affect clinical efficacy. Transformation of clopidogrel into its active metabolite requires the liver enzyme, cytochrome P450 2C19 (CYP2C19).13 PPIs also act through this enzyme, thereby reducing the enzyme’s bioavailability.14

With regard to clopidogrel metabolism in healthy individuals, carriers of a reduced-function allele of CYP2C19 had 30% lower levels of the active metabolite and a 25% relative reduction in platelet inhibition ex vivo.15 This suggests that CYP2C19 may affect the pharmacodynamics of clopidogrel in patients as well.

A clinical effect of CYP2C19 polymorphisms has been shown among patients using clopidogrel: carriers with a loss-of-function allele of CYP2C19 had 30% lower levels of the active clopidogrel metabolite and a 25% relative reduction in platelet inhibition ex vivo.15 This suggests that CYP2C19 may affect the pharmacodynamics of clopidogrel in patients as well.

METHODS
The methodology and report of the present review is based on the recommendations described in the PRISMA statement.  

Study selection
Eligible studies were identified by searching the following electronic databases: PubMed, Web-of-Science, Cochrane Database. In these databases, we combined the search terms ‘clopidogrel’ and ‘proton pump inhibitors’. The last search was performed on 12 June 2012. In addition, we scrutinised the reference lists of the eligible articles and the reviews, letters or editorials on this subject.

After removing duplicates, we excluded scientific meeting abstracts. Second, articles reporting no original study data (eg, reviews) were excluded. We only included studies written in European languages. There were no restrictions with respect to publication date or the type of PPI studied. Third, studies were excluded if there was no control group that consisted of clopidogrel users without adjunctive use of a PPI. Fourth, studies without data on platelet function test results and/or cardiovascular clinical outcomes were excluded.

Platelet function studies
Patients as well as healthy volunteers were considered. Crossover trials were accepted only for studies investigating healthy volunteers and only when a wash-out period of at least 10 days was used. In patient studies, we only included studies in which clopidogrel was administered in the setting of ACS (with or without coronary intervention) or after stent implantation for stable coronary disease. A crossover design was not accepted given the effect of time on platelet function after ACS and/or stent implantation. We excluded studies that only reported relative reductions between groups. In the case of reported relative reductions, an absolute measure of platelet function should be reported in at least one of the groups. No selection with regard to type of platelet function test used was made.

Clinical outcome studies
Patients using clopidogrel in the setting of ACS (with or without coronary intervention) or after stent implantation for stable coronary disease were considered; studies with other indications for clopidogrel were excluded. We also excluded studies that only reported relative reductions between groups. In the case of reported relative reductions, absolute numbers/proportions should be available in at least one of the groups.

End points
For the laboratory studies, we reviewed the results of reported platelet function tests. The end points for the clinical studies were all-cause mortality, MI and major adverse cardiac events (MACE) as defined by the authors of the original articles, which are outlined in the online appendices. We reported the outcome measures (i.e., RR, OR, HR) as reported by the author.

Quality assessment and data collection
We assessed the methodological validity of each included study using criteria for minimisation of bias. In detail, we determined the investigated populations, the possibility of exclusion bias, measurement of exposure, definition and measurement of outcome, blinding, length of follow-up, loss to follow-up, and control for confounders. In addition, for case-control studies, we assessed matching and the definition of cases and controls. No scales that numerically summarised the components were used.

Two investigators (JFF and MGHvO) independently performed the study selection. One investigator (JFF) then extracted study characteristics and data from the included studies using a prespecified data collection form and assessed the study quality. These data were validated by a second author (MGHvO). In the case of discrepancies, a third independent adjudicator (GECramer) was used. Reviewers were not blinded to the author, institution or journal.

Statistical analysis
Given the wide variety of laboratory parameters used as end points, outcome parameters cannot be pooled in comparisons of laboratory studies. Therefore we decided to review and describe the changes in platelet inhibition observed and not perform summarised quantitative comparisons.

For the clinical trials, we assessed the risk of publication bias across studies by visually evaluating a funnel plot. Notably, there were only two randomised trials among the clinical studies, and outcome data showed marked between-study heterogeneity: all-cause death, I² 83%, p<0.001; MI, I² 96%, p<0.001; MACE, I² 83%, p<0.001 (RevMan version 5.0, Copenhagen, 2008). As the terms and conditions for a sound meta-analysis were not met, a systematic review approach was adopted. Finally, we performed separate analyses for certain individual PPIs for the end point MACE.

RESULTS
We identified 838 hits with the search terms ‘clopidogrel’ and ‘proton pump inhibitors’.

After adjustment for duplicates, 577 unique records remained. After application of the exclusion criteria, 59 records remained (figure 1). Of these records, one reported data on both
laboratory and clinical end points, and one record addressed data for both healthy volunteers and patients.

**Laboratory studies**

The study characteristics are outlined in online appendix table 1 for healthy volunteers and online appendix table 2 for patients. Of the studies investigating healthy volunteers, 90% (9/10) were randomised studies. With regard to the 18 studies investigating patients, 61% (11/18) were of observational design. Only 28% (5/18) used random allocation of a PPI. The results of the 18 patient studies show that 11 (61%) reported significantly reduced inhibition of platelet aggregation in at least one platelet function test when PPIs were co-administered. In at least one platelet function test when PPIs were co-administered.

**Clinical studies**

The study characteristics are outlined in online appendix table 3. In only two of the 33 clinical studies was the use of a PPI randomised. Seven studies were prospective registries. There were three post hoc analyses of clinical data prospectively collected in the setting of a trial that randomised for stent treatment or for antithrombotic therapy. Nineteen were retrospective cohort studies, and two were case-control studies. Outcomes

**Larybro studies**

With regard to the studies investigating healthy volunteers, the main results are summarised in table 1 (more detailed description in online appendix table 4). In 70% (7/10) of the studies, addition of PPIs to clopidogrel resulted in significantly reduced platelet inhibition in at least one platelet function test. The results of the 18 patient studies show that 11 (61%) reported significantly reduced inhibition of platelet aggregation in at least one platelet function test when PPIs were co-administered. Of the five studies with random allocation of a PPI, only two reported a significant difference (table 1 and more detailed description in online appendix table 5).

**Clinical studies**

With regard to the baseline characteristics, there was a higher incidence of established prognosticators for adverse short- and long-term outcome among patients using PPIs, most prominent in the retrospective studies (online appendix table 6). The main results of the clinical studies are presented in table 2 (summarised description in online appendix table 7). Mortality was reported in 23 studies. In total, 17 (74%) articles reported no risk difference for patients on PPIs. In the other six studies, the effect ranged from a reduced risk in one study (adjusted HR 0.68, 95% CI 0.47 to 0.96) to an increased risk in five studies, with a RR of up to 2.63 (95% CI 1.17 to 5.94). The end point MI was reported in 25 studies, of which 11 (44%) reported a significantly increased RR for PPI users from 1.19 up to 4.58. The other 14 reported no difference in outcome. Of the 25 studies reporting MACE, 12 (48%) showed a significantly increased risk when PPIs were combined with clopidogrel, with an effect that ranged from HRs of 1.20–4.58. The other 13 studies showed no effect on outcome. When esomeprazole/omeprazole were examined as specific PPIs of interest, the reported effect of studies showed marked heterogeneity for the end point, MACE, as well: (es)omeprazole, I² 70%, p<0.01. Regarding (es)omeprazole, an increased risk was found in two of seven (29%) studies. The other five studies reported no significant risk difference.

The study characteristics are outlined in online appendix table 3. In only two of the 33 clinical studies was the use of a PPI randomised. Seven studies were prospective registries. There were three post hoc analyses of clinical data prospectively collected in the setting of a trial that randomised for stent treatment or for antithrombotic therapy. Nineteen were retrospective cohort studies, and two were case-control studies.

### Table 1 Summary of the results of the laboratory studies

<table>
<thead>
<tr>
<th>Population</th>
<th>Design</th>
<th>Number of studies</th>
<th>Total subjects (analysed)</th>
<th>Adverse effect of PPIs on at least one platelet function test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy volunteers</td>
<td>Randomised controlled trial</td>
<td>9</td>
<td>473 (441)</td>
<td>6/9 (67%)</td>
</tr>
<tr>
<td>Prospective study</td>
<td>1</td>
<td>21 (21)</td>
<td>1/1 (100%)</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>10</td>
<td>494 (462)</td>
<td>7/10 (70%)</td>
<td></td>
</tr>
<tr>
<td>Patients</td>
<td>Randomised controlled trial</td>
<td>5</td>
<td>505 (489)</td>
<td>2/5 (40%)</td>
</tr>
<tr>
<td>Post hoc analyses</td>
<td>2</td>
<td>131 (131)</td>
<td>2/2 (100%)</td>
<td></td>
</tr>
<tr>
<td>Observational studies</td>
<td>11</td>
<td>4815 (4815)</td>
<td>7/11 (64%)</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>18</td>
<td>5451 (5435)</td>
<td>11/18 (61%)</td>
<td></td>
</tr>
</tbody>
</table>

PPI, proton pump inhibitor.

DISCUSSION

The findings of this review are that the majority of laboratory studies suggest that the addition of certain PPIs reduces platelet inhibition ex vivo in clopidogrel users. The studies on clinical outcome are often not well designed, with signs of prescription bias and apparent imbalances in baseline characteristics, which mainly account for the large variability in the observed outcomes. It is only by acknowledgement of these aspects that reports suggesting harm from PPIs with RR increases up to 50% can be understood. Considering the firmly and thoroughly established relative benefit of about 20% from the addition of clopidogrel to aspirin, we feel that the reported magnitudes of increased risk cannot (solely) be attributed to the use of PPIs in many of these studies. Notably, nearly all prospective registries and, most importantly, the only two trials with random allocation of a PPI reported no detrimental clinical effect of PPIs in clopidogrel users.

Indisputably, in the (predominantly) randomised trials on healthy individuals using clopidogrel monotherapy, addition of certain PPIs has proven to reduce the inhibition of platelet aggregation as measured by multiple platelet function tests. This supports a pharmacological interaction ex vivo under physiological conditions.

In contrast, acute coronary disease differs from physiological conditions, and patients use both aspirin and clopidogrel. Patients with stable coronary disease who underwent revascularisation and stenting use dual therapy as well. Although about 60% (11/18) of laboratory studies suggest reduced platelet inhibition in the case of co-therapy with a PPI, these results should be interpreted with caution. Importantly, only five of the 18 studies on patients had random allocation of PPIs, two of which demonstrated impaired platelet inhibition. Notably, it has been suggested that PPIs may also adversely affect the platelet response to aspirin. This may be an additional reason for the observed reduced inhibition of platelet aggregation. Finally, some methodological issues characteristic of laboratory studies remain.

First, it is uncertain to what extent reproducibility contributes to the observed results, despite observed relative differences in laboratory outcome parameters of about 10–30%. A difference
<table>
<thead>
<tr>
<th>Design</th>
<th>Author</th>
<th>Number of patients (analysed)</th>
<th>PPIs used</th>
<th>Results for MI*</th>
<th>Results for all-cause mortality*</th>
<th>Results for MACE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>RCT</td>
<td>Bhatt, 2010†</td>
<td>3873 (3761)</td>
<td>O</td>
<td>HR 0.92 (95% CI 0.44 to 1.90)</td>
<td>RR 1.00 (95% CI 0.29 to 3.47)</td>
<td>HR 0.99 (95% CI 0.68 to 1.44)</td>
</tr>
<tr>
<td></td>
<td>Wu, 2011</td>
<td>665</td>
<td>P</td>
<td>n.r.</td>
<td>RR 1.03 (95% CI 0.66 to 1.60)</td>
<td>n.r.</td>
</tr>
<tr>
<td>Prospective data collection</td>
<td>Gaglia, 2010</td>
<td>820</td>
<td>P, O, L, R, E</td>
<td>n.r.</td>
<td>RR 2.63 (95% CI 1.17 to 5.94)</td>
<td>aHR 1.8 (95% CI 1.1 to 2.7)</td>
</tr>
<tr>
<td></td>
<td>Zairis, 2010</td>
<td>588</td>
<td>O</td>
<td>HR 1.0 (95% CI 0.5 to 1.9)</td>
<td>RR 1.1 (95% CI 0.4 to 2.7)†</td>
<td>PsAHR 1.08 (95% CI 0.53 to 2.22)</td>
</tr>
<tr>
<td></td>
<td>Tzenteris, 2010</td>
<td>1210</td>
<td>P, O, L, R</td>
<td>PsAHR 1.27 (95% CI 0.29 to 5.70)†</td>
<td>PsAHR 0.78 (95% CI 0.34 to 1.76)</td>
<td>PsAHR 1.08 (95% CI 0.53 to 2.22)</td>
</tr>
<tr>
<td></td>
<td>Rossini, 2010</td>
<td>370</td>
<td>P, O, L, R, E</td>
<td>n.r.</td>
<td>aOR 0.97 (95% CI 0.28 to 3.31)</td>
<td>PsAHR 0.89 (95% CI 0.63 to 1.27)</td>
</tr>
<tr>
<td></td>
<td>Tentzeris, 2010</td>
<td>1210</td>
<td>P</td>
<td>PsAHR 1.04 (95% CI 0.64 to 1.69)†</td>
<td>aHR 0.95 (95% CI 0.56 to 1.63)</td>
<td>aOR 1.54 (95% CI 0.60 to 4.02)</td>
</tr>
<tr>
<td></td>
<td>Ho, 2009</td>
<td>315</td>
<td>O</td>
<td>n.r.</td>
<td>RR 2.63 (95% CI 1.17 to 5.94)</td>
<td>n.r.</td>
</tr>
<tr>
<td></td>
<td>Gupta, 2010</td>
<td>16 50</td>
<td>P, O, L, R, E</td>
<td>n.r.</td>
<td>aHR 2.63 (95% CI 1.17 to 5.94)</td>
<td>n.r.</td>
</tr>
<tr>
<td></td>
<td>Rassen, 2009</td>
<td>1751</td>
<td>n.r.</td>
<td>n.r.</td>
<td>aHR 1.10 (95% CI 0.51 to 2.40)†</td>
<td>n.r.</td>
</tr>
<tr>
<td></td>
<td>Wang, 2009</td>
<td>20 96</td>
<td>P, O, L, R</td>
<td>n.r.</td>
<td>aHR 1.10 (95% CI 0.51 to 2.40)†</td>
<td>n.r.</td>
</tr>
<tr>
<td></td>
<td>Sarafoff, 2010</td>
<td>16 690</td>
<td>P, O, L, R</td>
<td>aOR 1.27 (95% CI 1.03 to 1.57)</td>
<td>aOR 1.04 (95% CI 0.49 to 2.18)</td>
<td>aHR 1.29 (95% CI 0.64 to 1.9)</td>
</tr>
<tr>
<td></td>
<td>Kreutz, 2010</td>
<td>2066</td>
<td>n.r.</td>
<td>aOR 1.22 (95% CI 1.05 to 1.55)</td>
<td>aHR 0.69 (95% CI 0.40 to 1.16)</td>
<td>aHR 1.11 (95% CI 1.39 to 1.64)</td>
</tr>
<tr>
<td></td>
<td>Stockl, 2010</td>
<td>5794</td>
<td>P, O, L, R, E</td>
<td>n.r.</td>
<td>aHR 1.22 (95% CI 1.13 to 1.42)</td>
<td>aHR 1.64 (95% CI 1.16 to 2.32)</td>
</tr>
<tr>
<td></td>
<td>Evanchan, 2010</td>
<td>876</td>
<td>O</td>
<td>n.r.</td>
<td>aHR 1.22 (95% CI 1.13 to 1.42)</td>
<td>aHR 1.29 (95% CI 1.17 to 1.42)</td>
</tr>
<tr>
<td></td>
<td>Chariot, 2010</td>
<td>3896</td>
<td>P, O, L, R, E</td>
<td>n.r.</td>
<td>n.r.</td>
<td>aHR 1.29 (95% CI 1.17 to 1.42)</td>
</tr>
<tr>
<td></td>
<td>Gaspar, 2010</td>
<td>386</td>
<td>O</td>
<td>aOR 1.86 (95% CI 1.57 to 2.20)§</td>
<td>aOR 1.04 (95% CI 0.49 to 2.18)</td>
<td>aHR 1.11 (95% CI 1.39 to 1.64)</td>
</tr>
<tr>
<td></td>
<td>Ortolani, 2010</td>
<td>1 800</td>
<td>O</td>
<td>aOR 1.22 (95% CI 0.95 to 1.57)</td>
<td>aHR 0.69 (95% CI 0.40 to 1.16)</td>
<td>aHR 1.39 (95% CI 1.39 to 1.64)</td>
</tr>
<tr>
<td></td>
<td>Yasu, 2010</td>
<td>18 690</td>
<td>P, O, L, R, E</td>
<td>n.r.</td>
<td>aHR 1.22 (95% CI 1.13 to 1.42)</td>
<td>aHR 1.64 (95% CI 1.16 to 2.32)</td>
</tr>
<tr>
<td></td>
<td>Hsu, 2010</td>
<td>38</td>
<td>P</td>
<td>aOR 1.22 (95% CI 0.95 to 1.57)</td>
<td>aHR 1.22 (95% CI 1.13 to 1.42)</td>
<td>aHR 1.29 (95% CI 1.17 to 1.42)</td>
</tr>
<tr>
<td></td>
<td>Hudzik, 2010</td>
<td>9753</td>
<td>P, O, L, R</td>
<td>aOR 1.04 (95% CI 0.49 to 2.18)</td>
<td>aHR 0.69 (95% CI 0.40 to 1.16)</td>
<td>aHR 1.29 (95% CI 1.17 to 1.42)</td>
</tr>
<tr>
<td></td>
<td>Hisao, 2010</td>
<td>188</td>
<td>O</td>
<td>aOR 1.04 (95% CI 0.49 to 2.18)</td>
<td>aHR 0.69 (95% CI 0.40 to 1.16)</td>
<td>aHR 1.29 (95% CI 1.17 to 1.42)</td>
</tr>
<tr>
<td></td>
<td>Ulhaq, 2011</td>
<td>397</td>
<td>P, O, L, R, E</td>
<td>n.r.</td>
<td>aOR 1.04 (95% CI 0.49 to 2.18)</td>
<td>aHR 1.29 (95% CI 1.17 to 1.42)</td>
</tr>
<tr>
<td></td>
<td>Lin, 2011</td>
<td>1887</td>
<td>O</td>
<td>aOR 1.22 (95% CI 0.95 to 1.57)</td>
<td>aHR 1.22 (95% CI 1.13 to 1.42)</td>
<td>aHR 1.29 (95% CI 1.17 to 1.42)</td>
</tr>
<tr>
<td></td>
<td>Ulhaq, 2011</td>
<td>397</td>
<td>O</td>
<td>aOR 1.22 (95% CI 0.95 to 1.57)</td>
<td>aHR 1.22 (95% CI 1.13 to 1.42)</td>
<td>aHR 1.29 (95% CI 1.17 to 1.42)</td>
</tr>
<tr>
<td></td>
<td>Ching, 2012</td>
<td>3876</td>
<td>O</td>
<td>aOR 1.22 (95% CI 0.95 to 1.57)</td>
<td>aHR 1.22 (95% CI 1.13 to 1.42)</td>
<td>aHR 1.29 (95% CI 1.17 to 1.42)</td>
</tr>
<tr>
<td>Case–control studies</td>
<td>Jaurlink, 2009</td>
<td>297</td>
<td>O</td>
<td>aOR 1.27 (95% CI 1.03 to 1.57)</td>
<td>aHR 0.99 (95% CI 0.68 to 1.44)</td>
<td>aHR 1.45 (95% CI 0.66 to 1.44)</td>
</tr>
<tr>
<td></td>
<td>Valkhoff, 2011</td>
<td>23 655</td>
<td>O</td>
<td>OR 5.67 (95% CI 0.89 to 5.92)</td>
<td>aOR 1.02 (95% CI 0.49 to 2.18)</td>
<td>aOR 1.02 (95% CI 0.49 to 2.18)</td>
</tr>
</tbody>
</table>

*Outcomes represent the risk ratio for combined use of clopidogrel and proton pump inhibitors.
†Study reported cardiovascular death.
‡Study reported acute coronary syndrome.
§Study reported rehospitalisation for acute coronary syndrome.
a, adjusted; E, esomeprazole; L, lansoprazole; MACE, major adverse cardiac events; MI, myocardial infarction; n.r., not reported; O, omeprazole; P, pantoprazole; PPI, proton pump inhibitor; PS, propensity score; R, rabeprazole; RCT, randomised controlled trial.
in laboratory results may be numerically statistically significant, but it depends on the coefficient of variation of the respective test whether there is a true difference between values. Second, issues with regard to the pharmacology of antiplatelet therapy have not been accounted for. It should be appreciated that the timing of the laboratory assessment in relation to the use of the antiplatelet therapy is often not systematically reported.

Although it is tempting to assume that a pharmacological interaction under physiological conditions will also be present in the setting of an ACS, the laboratory findings in patients are less uniform, which also holds true for the quality of the studies. The warnings issued for the combined use of certain PPIs and clopidogrel by the FDA were predominantly based on laboratory studies that showed reduced platelet inhibition and the hypothesis that this surrogate end point might result in a reliable meta-analysis. Moreover, in only two of the 33 controlled studies the PPI randomly allocated. Consequently, in most studies, imbalances were present with regard to well-established baseline predictors of adverse outcome, which were more common in PPI users. For example, in the study by Ho et al, the OR for all-cause mortality was 1.24 (95% CI 1.10 to 1.40), but after adjustment it changed to 0.91 (95% CI 0.80 to 1.05), indicating the importance of confounders in the observed results.12

Another explanation for the observed differences in outcome is indication/prescription bias. According to the latest guidelines, patients on dual antiplatelet therapy (i.e., aspirin and clopidogrel) are—by definition—at increased gastrointestinal risk and should consequently receive gastroprotective therapy in the form of PPIs.4 Interestingly, only 30–40% of patients were using PPIs. This low incidence of PPI prescription may be due to a delay in guidelines being applied in practice.76 It is plausible that physicians are more likely to withhold PPIs from the relatively healthy patients and preferentially prescribe them for patients with more comorbidity. Post hoc analyses of the PLATO trial corroborated this hypothesis and stated that PPI use should be interpreted more as a marker than a cause of higher cardiovascular event rates.52

To minimise the impact of the abovementioned factors, randomised PPI allocation is of the utmost importance. In the case of controlled studies without random allocation, other aspects of the study design are important. During our process of testing the criteria to perform meta-analysis, exploratory analyses showed that the heterogeneity was primarily caused by the retrospective studies (data not shown). Figure 2 provides insight into the distribution of point estimates of the prospective studies; there is no significant heterogeneity. If pooled estimates for the RR of PPIs were to be calculated, the prospective studies would result in an OR of 1.13 (95% CI 0.98 to 1.30), mutually exclusive from the 95% CI of the retrospective studies (OR 1.63, 95% CI 1.45 to 1.83).

The largest of the two studies with random allocation of a PPI, the COGENT trial, included 3873 patients, with a median follow-up of 106 days, and reported no significant difference in cardiovascular outcome for adjunctive use of omeprazole in clopidogrel users.12 This result is especially interesting since omeprazole has most often been implicated with regard to warnings based on laboratory findings and observational data on clinical outcome. Notably, if pooled estimates for (es)omeprazole and pantoprazole were to be calculated (online appendix figure 1A, B, respectively), an adverse effect of PPIs on outcome would have been present only for pantoprazole (OR 1.54, 95% CI 1.13 to 2.09). This is one more indication that other factors are of more importance to the observed adverse clinical outcome than the observed pharmacological effect of the individual PPIs in the laboratory.

In summary, 40–50% of the studied records suggested adverse outcome in the case of co-administration of PPIs for the end points, MI and MACE, whereas for mortality this percentage was 22%. In view of the above mentioned methodological aspects, we feel that the many reports suggesting risk increases that are ‘out of proportion’—that is, more than the relative benefit of 20% that can be achieved with clopidogrel treatment2 77 78—should be interpreted with caution.
In view of the above, only well-designed, randomised trials powered to assess the effect on cardiac events can address the potential adverse effect of adjunctive PPI use in patients on clopidogrel. Until then, methodological flaws in laboratory studies, the fact that there is no one-to-one translation of impaired ex vivo platelet inhibition into adverse clinical outcome, and the marked heterogeneity observed in the clinical studies preclude a definitive conclusion. Emerging evidence from recent prospective studies do not support the statement that the addition of PPIs in patients who use clopidogrel should be considered harmful. The suggestion that the potential adverse effect may not hold true for pantoprazole and should especially be considered if omeprazole is prescribed is based on pharmacological assumptions and laboratory measurements, but is contradicted by the available clinical evidence.

Study limitations
As clopidogrel is predominantly prescribed in the setting of ACS or after coronary stent implantation for stable coronary disease, we defined our population accordingly. As a consequence, clopidogrel administration for other indications such as stroke prevention were not included in our analyses. Notably, for these less common indications, the lack of well-designed studies on the effect of PPIs also holds true. With regard to the selection process of the reviewed studies, data presented in the form of an abstract only were not considered. However, the funnel plot did not indicate publication bias. It can be considered a limitation that we do not provide a summarised quantitative effect of the reported studies. As outlined above, we feel there are several arguments not supporting the strategy of meta-analysis. In view of this, we addressed the question whether there are potential differences in effect between the various PPIs (pantoprazole vs esomeprazole) only in the form of data review.

Conclusions and implications
In summary, there is clear ex vivo evidence of a pharmacological interaction between clopidogrel and PPIs in healthy individuals. In contrast, data for patients—who use both clopidogrel and aspirin—are less uniform.

To date, the available clinical evidence does not support the statement that PPI co-administration will adversely affect clinical outcome in patients treated with clopidogrel. These findings once again fuel the discussion with regard to the use of ex vivo data as a surrogate end point for clinical outcome. Moreover, it should be realised that summarised quantitative overviews on this subject are mainly driven by non-randomised, retrospective studies, with apparent differences in baseline characteristics and prescription bias.

These observations fuel the debate on this controversial issue and call for recommendations based on well-designed clinical trials.

Acknowledgements
We thank GE Cramer for critically reviewing this paper and for serving as an independent adjudicator in the selection of the included studies. We gratefully acknowledge JL Bonnies for critically revising the manuscript.

Contributors
Conception and design: JIF, MAB, MGHvO, AL, DLB, FWV. Collection and assembly of data: JIF, MGHvO. Analysis and interpretation of data: JIF, MAB, MGHvO. Drafting of the manuscript: JIF, MAB, MGHvO. Critical revision: AL, DLB, FWV. Final approval of the manuscript: all authors.

Competing interests
MGHvO has served as a consultant for and has received unrestricted grant support from AstaZeneca, Nycomed and Pfizer; AL has served as a consultant for AstraZeneca, Pfizer and Bayer AG; DLB discloses the following relationships - Advisory Board: Medscape Cardiology; Board of Directors: Boston VA Research Institute, Society of Chest Pain Centers; Chair: American Heart Association Get With The Guidelines Science Subcommittee; Honoraria: American College of Cardiology (Editor, Clinical Trials, CardioSourse), Duke Clinical Research Institute (clinical trial steering committees), Slack Publications (Chief Medical Editor, Cardiology Today Intervention), WebMD (CME steering committees); Other: Senior Associate Editor, Journal of Invasive Cardiology, Research Grants: Amarin, AstaZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Medtronic, Sanofi Aventis, The Medicines Company; Unfunded Research: FlowCo, Plx Pharma, Takeda, and Chair of the COGENT study. FWV has received educational and research grants from Bayer AG, Roche, Eli Lilly and Boehringer Ingelheim and has received honoraria for consultancies from Daichi Sankyo, Eli Lilly, Merck, The Medicines Company and Bayer AG.

Provenance and peer review
Not commissioned; externally peer reviewed.

REFERENCES
Review


Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review

Jeroen Jaspers Focks, Marc A Brouwer, Martijn G H van Oijen, Angel Lanas, Deepak L Bhatt and Freek W A Verheugt

Heart 2013 99: 520-527 originally published online July 31, 2012
doi: 10.1136/heartjnl-2012-302371

Updated information and services can be found at:
http://heart.bmj.com/content/99/8/520

These include:

Supplementary Material
Supplementary material can be found at:
http://heart.bmj.com/content/suppl/2012/07/30/heartjnl-2012-302371.DC1.html

References
This article cites 71 articles, 11 of which you can access for free at:
http://heart.bmj.com/content/99/8/520#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Drugs: cardiovascular system (8631)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/